Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first oral once-daily treatment for acromegaly targeting patients with inadequate surgical response or inoperable cases. This rare endocrine disorder, driven by excessive pituitary growth hormone, has been traditionally treated with injectable drugs from Novartis and Ipsen. The approval positions Crinetics to challenge established therapies with a more convenient oral option. The drug’s priority review underscores its potential impact in transforming acromegaly care and expanding patient choices.